Pavan Bhausaheb Udavant

Dr. Pavan Bhausaheb Udavant

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2023 in Heliyon
Verified
Journal Article
Open access
NDNeelam Dashputre
Neelam Dashputre
ULUmesh D. Laddha
Umesh D. Laddha
PDPrajakta P. Darekar
Prajakta P. Darekar
JKJayesh D. Kadam
Jayesh D. Kadam
SPSurbhi B. Patil
Surbhi B. Patil
SKSanjay J. Kshirsagar
Sanjay J. Kshirsagar
Alzheimer's disease (AD) is the most prevalent type of dementia which has been affected to more the 44 million people globally. It is distinguished by gradually deteriorating memory and other cognitive abilities that precede dementia. Present treatment of AD mainly focuses on symptomatic slowing the evolution of the disease which is associated with numerous side effects such as dizziness, tiredness, nausea, vomiting, heart attack, and stroke etc. Henceforth; there is urgent need to identify the alternative treatment for management of AD. Herbal medicines have been used from long time to treat AD. One of such leading Phyto molecule is Naringin. It showed promising results against AD but suffers from poor bioavailability and require in high dose to cross the blood brain barrier. The main objectives of proposed work are to increase the bioavailability of naringin in brain by developing Nano-suspension and preclinical evaluation of neuroprotective effect of Naringin Nano-suspension (NNS) against Scopolamine induced Alzheimer's disease in rats. The present study deals with the development, characterization of NNSand to evaluate neuroprotective effect of NNS. Nanoparticles of drug were formed by using PLGA polymer and optimized by using 32 factorial design. Optimized batch was further characterized by scanning electron microscopy (SEM) and X-ray diffraction (XRD). Further the effectiveness of NNS was preclinically investigated by performing AOTstudy as per OECD guideline 420. AD induced Albino Wistar Rats were treated with NNS orally for 14 days and then evaluated for parameters like Gross examination of brain, Relative brain weight determination, behavioural parameters, neuro-inflammatory parameters and immune-histology. Optimization was carried out to study the effect of polymer concentration and number of HPH cycles on Particle size, Poly dispersity index (PDI) and % entrapment efficiency. Desirability search approach was used to select the optimized formulation. Based on the selection criteria, batch F6 having 357.6 ± 05 nm particle size, 0.168 ± 0.04 PDI and 91 ± 2% EE was selected as optimized batch. SEM analysis showed spherical morphology and XRD confirmed the molecular dispersion. Pre-treatment with NNS showed neuroprotective activity basedon results of behavioural studies, biochemical estimation, neuroinflammatory parameters and immunohistochemistry evaluations. As NNS showed significant neuroprotective and anti-neuro-inflammatory effect, this study opens up new ways to exploit Naringin for various therapeutic and restorative purposes.

24 September 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
ULUmesh D. Laddha
Umesh D. Laddha
SKSanjay J. Kshirsagar
Sanjay J. Kshirsagar
LSLayba S. Sayyad
Layba S. Sayyad
MAMusab T. Ahmed
Musab T. Ahmed
SGSachin S. Gaikwad
Sachin S. Gaikwad
AKAbhijeet Dattatraya Kulkarni
Abhijeet Dattatraya Kulkarni

23 October 2023 in European Journal of Medicinal Chemistry Reports
Verified
Journal Article
Open access
NDNeelam Dashputre
Neelam Dashputre
JKJayesh D. Kadam
Jayesh D. Kadam
ULUmesh D. Laddha
Umesh D. Laddha
SPSurabhi B. Patil
Surabhi B. Patil
PUPavan Bhausaheb Udavant
Pavan Bhausaheb Udavant
SKSmita P. Kakad
Smita P. Kakad

20 June 2021 in Ars Pharmaceutica (Internet)
Verified
Journal Article
Open access
PDF file
MPMoreshwar Patil
Moreshwar Patil
PPPrashant Pandit
Prashant Pandit
PUPavan Bhausaheb Udavant
Pavan Bhausaheb Udavant
SSSandeep Sonawane
Sandeep Sonawane
DBDeepak Bhambere
Deepak Bhambere
Introducción: Etodolac se usa en el tratamiento del dolor agudo y la inflamación. Tiene baja solubilidad debido a la alta hidrofobia y se informa que tras la administración oral muestra alteraciones gástricas. Esto fomenta el desarrollo de formulación tópica en lugar de oral. Método: En este trabajo utilizamos el método de separación de fase de coacervación para el desarrollo del sistema vesicular cargado con etodolaco mediante el uso de tensioactivos no iónicos, colesterol y lecitina de soja. El diseño central compuesto (rotativo) se utilizó para optimizar las concentraciones de lecitina de soja, surfactante y colesterol. Las formulaciones preparadas se caracterizaron por análisis de tamaño de vesículas, potencial zeta, eficiencia de atrapamiento, permeación in vitro, permeación ex vivo y estudio antiinflamatorio. Resultados: Etodolac quedó atrapado con éxito en todas las formulaciones que tenían una eficiencia en el intervalo de 74,36% a 90,85%, siendo mayor a 4 ° C que a temperatura ambiente. Cuando se hidrata con agua, los niosomas se producen espontaneamente el rango de 54 a 141 (por mm cúbico). Los resultados del estudio de difusión in vitro revelaron que el etodolaco se liberó en un rango de 71,86 a 97,16% durante un período de 24 horas. El tamaño medio de vesícula de la formulación optimizada se encontró en 211,9 nm con un PDI de 0,5. Las respuestas observadas, es decir,% de eficacia de encapsulación y liberación de fármaco, fueron 74,12 y 95,08 respectivamente. El potencial zeta fue de -19,4 mV y reveló la estabilidad de la formulación, que fue confirmada adicionalmente por la ausencia de cambios en el contenido del fármaco y la liberación del fármaco después de los estudios de estabilidad. El% de inhibición en el volumen de la pata fue del 40,52% y del 43,61% para la prueba y el gel proniosómico comercializado. Conclusión: la formulación de gel proniosomal fue estable y podría mejorar el suministro de etodolaco a la piel debido a la excelente capacidad de permeación del sistema vesicular.

30 June 2022 in Biosciences Biotechnology Research Asia
Verified
Journal Article
Open access
SASapana Ahirrao
Sapana Ahirrao
DBDeepak Bhambere
Deepak Bhambere
KTKunal Todkar
Kunal Todkar
MPMoreshwar Patil
Moreshwar Patil
PKPallavi Khairnar
Pallavi Khairnar
ABAnagha Baviskar
Anagha Baviskar
Zolmitriptan is the antimigraine agent widely used for the treatment of the migraine. It shows the half-life of 2.5 – 3 h which indicate the frequent dosing to achieve proper pharmacological action of the drug. Gastro Retentive Drug Delivery System (GRDDS) is a common approach to decrease the dosing frequency and increase patient compliance, and delivery of drug through such an approach of floating tablet formulation will meet the requirement. This system showed substantial effect on the drug release through floating and swelling properties. The tablets were formulated by using direct compression technique along with hydrophilic polymers and gas generating system. In the preliminary trials, we observed that the tablets were within pharmacopeial limit. % Drug release of the formulations (F1 – F9) was studied up to 6 h and it was found from 52 to 91 %. The cumulative percentage drug release was inversely proportional to polymer concentrations of HPMC K100 M and PVP K 30. The batches follow Higuchi model of drug release which involves the diffusion mechanism. In-vitro dissolution studies showed good percent drug release, which is in accordance with robinson-errikson equation. Good buoyancy for additional 6 h, trailed by the diffusion.

21 March 2023 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
PUPavan Bhausaheb Udavant
Pavan Bhausaheb Udavant
PGPragati Gurav
Pragati Gurav
GKGayatri Kanade
Gayatri Kanade
NDNeelam Dashputre
Neelam Dashputre
RSRahul Sable
Rahul Sable
HRHemant Raut
Hemant Raut
Introduction: Hepato-renal toxicity is a devastating, non-communicable disease. Because of a lack of information on low-cost management to combat the disease, this study postulates the ameliorative effect of selected phytoconstituents against toxicity. Aim and Objective: The current study reveals an active phytoconstituent, α- Pinene, that has the ability to combat the degenerative effects of CCl4. Methodology: Carbon tetrachloride (CCl4) is an organic xenobiotic molecule as well as the most potent hepatotoxic agent used (1200 mg/kg body weight; i.p.) to induce hepato-renal toxicity in experimental rats. To determine in vivo hepato-renal toxicity, three different doses (0.05 ml/kg body weight, 0.1 ml/kg body weight, and 0.15 ml/kg body weight; intraperitoneally) were chosen. Vitamin C at the dose of 250 mg/kg/p.o. was used as a standard, due to its maximum ameliorative activity against oxidative damage in CCl4-induced hepato-renal toxicity in rats. For 7 days, the animals were pre-treated with α-pinene and Vitamin C. CCl4 was charged only on the 7th day. Result and Conclusion: The related biochemical tests were studied. CCl4 intoxication reduces mitochondrial membrane potential in liver and kidney cells, which accelerates excessive intracellular ROS production, but α-pinene pretreatment successfully restores it in both liver and kidney cells. Pretreatment with α-pinene and vitamin C for 7 days increased intracellular ameliorative capability in hepatic and renal cells significantly (p 0.01). In conclusion, α-pinene is capable of restoring antioxidant status by quenching intracellular ROS. As a result, α-pinene has the potential to provide hepatoprotective and nephroprotective effects against CCl4-induced toxicity in rats.